First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in its named patient program...

Related Keywords

Australia ,Canada ,Japan ,Melbourne ,Victoria ,Italy ,Switzerland ,Milan ,Lombardia ,United States ,Netherlands ,Belgium ,Australian ,Cdx Zircaix ,Kyahn Williamson ,Arturo Chiti ,Telix Pharmaceuticals Limited ,Ministry Of Health ,Drug Administration ,Linkedin ,Australian Securities Exchange ,Australian Therapeutic Goods Administration ,Health Canada ,Telix Pharmaceuticals ,Corporate Communications ,San Raffaele ,Diagnostic Imaging ,Molecular Biopsy ,Telix Medical Director ,Middle East ,Biologics License Application ,Offering Compassionate Use ,Investigational Medicines ,